Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/17055
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJohn, Thomas-
dc.contributor.authorChia, Puey Ling-
dc.date2018-
dc.date.accessioned2018-01-23T00:33:46Z-
dc.date.available2018-01-23T00:33:46Z-
dc.date.issued2018-01-19-
dc.identifier.citationClinical cancer research : an official journal of the American Association for Cancer Research 2018; online first: 19 January-
dc.identifier.issn1078-0432-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/17055-
dc.description.abstractCell-lines formed from an individual's tumor can be used to predict response to specific therapies and determine genomic predictors. For mesothelioma, where chemotherapy remains the backbone of current therapeutic paradigms, such assays could be used to treat patients with the most effective agents specific to their "chemical profile".-
dc.language.isoeng-
dc.titlePersonalized chemosensitivity assays for mesothelioma- is it worth the effort?-
dc.typeJournal Article-
dc.identifier.journaltitleClinical cancer research : an official journal of the American Association for Cancer Research-
dc.identifier.affiliationMedical Oncology, Olivia Newton John Cancer Research Institute-
dc.identifier.affiliationMedical Oncology, University of Melbourne, Olivia Newton John Cancer Research Institute.-
dc.identifier.pubmedurihttps://www.ncbi.nlm.nih.gov/pubmed/29351918-
dc.identifier.doi10.1158/1078-0432.CCR-17-3493-
dc.identifier.pubmedid29351918-
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.